Keytruda Keeps Racking Up Approvals and Clinical Wins in ’23

The Inflation Reduction Act could put an end to blockbuster runs like that of Merck’s Keytruda, experts told BioSpace. In the meantime, the drug keeps picking up more indications and positive clinical results.

Scroll to Top